Celltrion, Inc. (068270)の価格はいくらですか

Celltrion, Inc. (068270)の価格は$131.80です

Celltrion, Inc. (068270)の時価総額は何ですか

Celltrion, Inc. (068270)の時価総額は$30.23Bです

Celltrion, Inc.（068270）配当金

Celltrion, Inc., a South Korean biopharmaceutical company, specializes in the development and manufacturing of protein-based therapies, including treatments for oncology. Its commercial portfolio features established products such as Remsima, Truxima, and Herzuma, alongside a range of generic pharmaceuticals and diagnostic kits for COVID-19. The company maintains an extensive pipeline of antibody biosimilars currently undergoing various stages of clinical evaluation. Late-stage (Phase 3) candidates include CT-P17, aimed at rheumatoid arthritis, psoriatic arthritis, and inflammatory bowel disease (IBD); CT-P16, targeting metastatic colorectal and breast cancers; CT-P43, for inflammatory conditions like psoriasis, Crohn's disease, and ulcerative colitis; CT-P42, addressing diabetic macular edema; and CT-P59, developed for COVID-19. In Phase 2, CT-P27 is being tested for pandemic and seasonal influenza. Earlier in development, Phase 1 assets comprise CT-P39 for asthma and urticaria, CT-P41 for osteoporosis and bone loss, and CT-G20 for cardiomyopathy. Additionally, Celltrion maintains a collaboration with Inhalon Biopharma, Inc. to advance IN-006, an inhaled formulation of regdanvimab intended for the treatment of COVID-19 patients. Established in 2002, the company operates primarily from its headquarters in Incheon, South Korea.

年	配当（株式分割調整済み）	変化
提供された日付のデータは十分ではありません。

年

配当（株式分割調整済み）

変化

提供された日付のデータは十分ではありません。

年	配当	変化
提供された日付のデータは十分ではありません。

年

配当

変化

提供された日付のデータは十分ではありません。

企業	配当支払い回数	国
Vertex Pharmaceuticals Incorporated VRTX.US	0.00%	US
Argenx SE ARGX.US	0.00%	NL
CSL Limited CSL.AX	64.00%	AU
Moderna, Inc. MRNA.US	0.00%	US
Lonza Group AG LONN.SW	0.00%	CH

企業

配当支払い回数

国